
07/31/2025
Results of the KEYNOTE-689 trial indicate that clinicians can begin using immune checkpoint inhibitors perioperatively in surgically treated patients with squamous cell carcinoma of the head and neck, writes Dr. Hyunseok Kang. https://jwat.ch/4fePUGA